Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Journal of Neurology|March 21, 2009
Immunomodulatory treatment strategies in multiple sclerosisBernd C Kieseier, Heinz Wiendl, Verena I Leussink, et al.Therapeutic Advances in Neurological Disorders|July 2, 2016
Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathiesVerena I Leussink, Hans-Peter Hartung, Bernd C Kieseier, et al.Archives of Neurology|February 11, 2009
Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosisOlaf Stüve, Verena I Leussink, Ruth Fröhlich, et al.Clinical Immunology (Orlando, Fla.)|July 8, 2011
Cladribine as a therapeutic option in multiple sclerosisClemens Warnke, Verena I Leussink, Norbert Goebels, et al.Neurology|November 2, 2014
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopeniaClemens Warnke, Thomas Dehmel, Ryan Ramanujam, et al.JAMA Neurology|April 20, 2013
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responsesBernd C Kieseier, Olaf Stüve, Thomas Dehmel, et al.Brain Communications|November 10, 2021
Relapse-independent multiple sclerosis progression under natalizumabJonas Graf, Verena I Leussink, Giulia Soncin, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 10, 2014
Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD miceGerd Meyer zu Horste, Anne K Mausberg, Steffen Cordes, et al.Annals of Clinical and Translational Neurology|January 4, 2018
Infectious risk stratification in multiple sclerosis patients receiving immunotherapyJonas Graf, Verena I Leussink, Thomas Dehmel, et al.Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.Pageof 1